← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. GILD
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargetsShould I Buy?

GILD logoGilead Sciences, Inc. (GILD) P/E Ratio History

Historical price-to-earnings valuation from 2001 to 2025

Current P/E
358.7
Overvalued
5Y Avg P/E
101.3
+254% vs avg
PE Percentile
95%
High
PEG Ratio
N/A
N/A
TTM EPS$6.79
Price$136.30
5Y PE Range11.9 - 931.6
Earnings Yield0.28%

Loading P/E history...

GILD Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
358.7vs101.3
+254%
Premium vs History
vs. Healthcare
358.7vs22.2
+1519%
Above Sector
vs. S&P 500
358.7vs25.2
+1322%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -92% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 6, 2026, Gilead Sciences, Inc. (GILD) trades at a price-to-earnings ratio of 358.7x, with a stock price of $136.30 and trailing twelve-month earnings per share of $6.79.

The current P/E is 254% above its 5-year average of 101.3x. Over the past five years, GILD's P/E has ranged from a low of 11.9x to a high of 931.6x, placing the current valuation at the 95th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.2x, GILD trades at a 1519% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 178.0x.

Relative to the broader market, GILD commands a significant premium over the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GILD DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GILD P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ABBV logoABBVAbbVie Inc.
$363B86.5--1%
BMY logoBMYBristol-Myers Squibb Company
$115B16.4-+178%
AMGN logoAMGNAmgen Inc.
$179B23.37.91+88%
BIIB logoBIIBBiogen Inc.
$28B21.6--21%
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$75B17.42.75+8%
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$109B27.93.37+837%
MRK logoMRKMerck & Co., Inc.
$280B15.60.73Best+8%
PFE logoPFEPfizer Inc.
$151B19.5--4%
JNJ logoJNJJohnson & Johnson
$541B38.8--58%
INCY logoINCYIncyte Corporation
$20B15.6Lowest-+4173%Best

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

GILD Historical P/E Data (2001–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$122.74$6.7718.1x-65%
FY2025 Q3$111.00$6.4517.2x-67%
FY2025 Q2Mon Jun 30 2025 00:00:00 GM$110.87$5.0222.1x-58%
FY2025 Q1Mon Mar 31 2025 00:00:00 GM$112.05$4.7523.6x-55%
FY2024 Q4$92.37$0.37249.6x+377%
FY2024 Q3Mon Sep 30 2024 00:00:00 GM$83.84$0.09931.6x+1681%
FY2024 Q2Sun Jun 30 2024 00:00:00 GM$68.61$0.8283.7x+60%
FY2024 Q1Sun Mar 31 2024 00:00:00 GM$73.25$0.36203.5x+289%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$81.01$4.5018.0x-66%
FY2023 Q3Sat Sep 30 2023 00:00:00 GM$74.94$4.6616.1x-69%
FY2023 Q2Fri Jun 30 2023 00:00:00 GM$77.07$4.3517.7x-66%
FY2023 Q1Fri Mar 31 2023 00:00:00 GM$82.97$4.4318.7x-64%

Average P/E for displayed period: 52.3x

Full GILD Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

Should I Buy GILD Right Now?

Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.

See Verdict

See GILD's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is GILD Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare GILD vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

GILD — Frequently Asked Questions

Quick answers to the most common questions about buying GILD stock.

Is GILD stock overvalued or undervalued?

GILD trades at 358.7x P/E, above its 5-year average of 101.3x. The 95th percentile ranking indicates a premium to historical valuation.

How does GILD's valuation compare to peers?

Gilead Sciences, Inc. P/E of 358.7x compares to sector median of 22.2x. The premium reflects expected growth above peers.

What is GILD's PEG ratio?

GILD PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2001-2025.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

GILD P/E Ratio History (2001–2025)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.